The effect of selenium administration on complete blood count in elderly patients admitted to critical care unit

Status

Recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20091012002582N23

Enrollment

Registered

2021-05-18

Start date

2021-05-22

Completion date

Unknown

Last updated

2021-05-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Other infectious disease. Other infectious disease

Interventions

Intervention 1: Intervention group: Patients in the intervention group will receive bollus administraion of IV selenium (3000 µg) (produced by Biosyn company, Germany) during 3 hours at the beginning,

Eligibility

Sex/Gender

All

Age

60 Years to 100 Years

Inclusion criteria

Inclusion criteria: patients above 60 years admitted to critical care unit APACHE II above 15

Exclusion criteria

Exclusion criteria: History of malignancy Renal failure Suppression of the immune system

Design outcomes

Primary

Measure	Time frame
Platelet. Timepoint: days 1th and 10th. Method of measurement: Complete blood count.	—

Secondary

Measure	Time frame
Red Cell Distribution Width. Timepoint: Days 1th and 10th. Method of measurement: Complete blood count.;The ratio of neutrophils to lymphocytes. Timepoint: Days 1th and 10th. Method of measurement: Complete blood count.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactAta Mahmoodpoor

Tabriz University of Medical Sciences

amahmoodpoor@yahoo.com+98 41 3336 4667

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026